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Background: Low p27 and high Skp2 immunoreactivity are associated with a poor prognosis and other poor
prognostic features including resistant phenotypes and antiestrogen drug resistance. We investigated these
proteins in two International Breast Cancer Study Group trials studying node-negative early breast cancer.
Patients and methods: Trial VIII compared chemotherapy followed by goserelin with either modality alone in
premenopausal patients. Trial IX compared chemotherapy followed by tamoxifen with tamoxifen alone in
postmenopausal patients. Central Pathology Office assessed p27 and Skp2 expression in the primary tumor by
immunohistochemistry among 1631 (60%) trial patients.
Results: p27 and Skp2 were inversely related; 13% of tumors expressed low p27 and high Skp2. Low p27 and high
Skp2 were associated with unfavorable prognostic factors including larger size and higher grade tumors, absence of
estrogen receptor and progesterone receptor, human epidermal growth factor receptor 2 overexpression and high
Ki-67 (each P < 0.05). Low p27 and high Skp2 were not associated with disease-free survival (P = 0.42 and P = 0.48,
respectively). The relative effects of chemo-endocrine versus endocrine therapy were similar regardless of p27 or
Skp2.
Conclusions: We confirm the association of low p27 and high Skp2 with other poor prognostic features, but found
no predictive or prognostic value, and therefore do not recommend routine determination of p27 and Skp2 for
node-negative breast cancer.
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introduction
The prognosis of patients with early breast cancer is primarily
determined by traditional tumor factors such as tumor stage,
size, extent of nodal spread and the presence or absence of
metastases [1]. The biological markers estrogen receptor (ER),
progesterone receptor (PgR) and human epidermal growth
factor receptor 2 (HER2) have been widely accepted for routine
use, serving also as predictors of therapy responsiveness [2].
p27 is a member of the Cip/Kip family of cyclin-dependent
kinase inhibitors, expressed at a high level in G0 cells, which
promotes cell cycle arrest and apoptosis. The S-phase
kinase-associated proteins Skp2 are required for the
ubiquitination and consequent degradation of p27 which
allows cells to enter the S-phase.
In breast tumors, low p27 and high Skp2 are more
frequently associated with ER-negative phenotype, high
histological grade and poor prognosis. Traub et al. [3]
described low p27/high Skp2 as a poor prognostic factor and
identified a subset with Skp2 expressed at low levels despite
low p27, perhaps due to low levels but hyperactive Skp2 or
other molecular mechanisms [4]. In early-stage breast
carcinoma, a decreased immunoreactivity for p27 was
correlated with HER2 overexpression and with benefit from
one course of perioperative chemotherapy [5]. Furthermore,
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a deregulated expression of Skp2 in breast cancer cells might
have a relevant role in the development of resistance to
antiestrogen drugs, whereas a normal p27 expression could be
considered an independent predictor of responsiveness to
hormonal therapy [6]. Other papers report a higher Skp2
expression in a subset of ER-negative aggressive breast
carcinomas [7] and the development of trastuzumab
resistance in association with loss of p27 nuclear expression
in breast cancer cells [8].
The present studywas designed to assess whether p27 and Skp2,
alone or together, could be useful to identify subgroups of
patients more likely to benefit from adjuvant endocrine or
chemo-endocrine treatments and to analyze their prognostic
and predictive value in comparisonwith previously reported data.
For this purpose, we have chosen patients enrolled in two
randomized clinical trials comparing adjuvant endocrine therapy
and/or chemotherapy in node-negative invasive breast cancer.
patients and methods
International Breast Cancer Study Group trials VIII and IX
International Breast Cancer Study Group (IBCSG) trials VIII and IX [9, 10]
were randomized clinical trials comparing adjuvant endocrine therapy
alone and sequential chemotherapy followed by endocrine therapy for
node-negative invasive breast cancer among premenopausal (trial VIII) and
postmenopausal (trial IX) patients. In both trials, patients with ER-positive,
ER-negative and ER-unknown tumors (ER-unknown status allowed only if
ER determination was not possible because of lack of tumor material) were
eligible until 1998; at that time, protocol amendments restricted enrollment
to patients with ER-positive tumors. Over 94% of patients were
randomized before the amendments’ release. Institutional review boards
reviewed and approved the protocols, and an informed consent was
required according to the criteria established within the individual
countries.
treatment regimens
Trial VIII evaluated whether sequential treatment with six 28-day courses
of ‘classical’ cyclophosphamide, methotrexate, fluorouracil (CMF)
chemotherapy followed by 18 monthly s.c. implants of goserelin
significantly improved disease-free survival (DFS) as compared with
either six 28-day courses of classical CMF alone or 24 monthly implants
of goserelin alone. From 1990 through 1999, a total of 1063 assessable
pre/perimenopausal patients with node-negative disease were randomized
[9]. Trial IX evaluated whether sequential treatment with three 28-day
courses of classical CMF chemotherapy followed by tamoxifen for 57
months significantly improved DFS as compared with tamoxifen alone for
5 years. From 1988 through 1999, a total of 1669 eligible and assessable
postmenopausal patients with node-negative disease were randomized [10].
pathology cohort
Retrospective tissue collection was carried out for patients randomized in
IBCSG trials VIII and IX in accordance with institutional guidelines and
national laws. Archival tumor material (blocks and/or slides) was
available and assessable by the IBCSG Central Pathology Laboratory
among 953 of 1063 (90%) trial VIII patients and 1541 of 1669 (91%)
trial IX patients. About 30% of patients had only four unstained slides
available which were used for ER, PgR, HER2 and Ki-67 labeling index
(LI)—and their tumors could not be assessed for p27 and Skp2
expression. Thus, material was available to assess p27 and Skp2 among 647
(61%) of 1063 trial VIII patients and 984 (59%) of 1669 trial IX patients.
immunohistochemistry
In the IBCSG Central Pathology Laboratory in Milan, Italy, expression of
ER, PgR, HER2, Ki-67, p27 and Skp2 in the primary tumors was
determined by immunohistochemistry (IHC) as previously described [11]
without knowledge of treatment assignment or outcome. The tumor
sections were incubated with the specific primary monoclonal antibodies to
ER (Dako, Glostrup, Denmark, clone 1D5, 1 : 100 dilution), PgR (Dako,
clone 1A6, 1 : 800 dilution), Ki-67 (Dako, clone Mib-1, 1 : 200 dilution),
p27 (Transduction Laboratories, Lexington, KY, 1 : 600 dilution) and Skp2
(Zymed, San Francisco, CA, clone: 1G12E9, 1 : 10 dilution). HER2/neu
immunoreactivity was evaluated using the HercepTest kit (Dako), as
recommended by the manufacturer, and the tumors were scored for the
intensity of immunostaining, the completeness of cell membrane staining
and the percentage of immunoreactive neoplastic cells by using a four-tier
scale (from 0 to 3+), as recommended by the Food and Drug
Administration [12].
statistical methods
ER and PgR status were classified by dichotomizing IHC expression as
present (‡1% immunoreactive cells) or absent (0%). HER2 was considered
as overexpressed if the intensity was scored 3+. Ki-67 LI was classified as
high for ‡19% immunoreactive cells which was the median value of
distribution [13]. Tumor p27 expression was considered as low for <50%
and normal for ‡50% immunoreactive cells [5, 14] and Skp2 expression
was considered as high for ‡10% immunoreactive cells [4], which
corresponded closely to a cut point of >5% immunoreactive cells [3]
because few tumors were scored in the range of 6%–9% immunostaining.
Logistic regression modeling was used to examine the association of
tumor grade and size, ER, PgR, HER2 and Ki-67 LI expression and the
interactions of these variables with both p27 and Skp2 status,
controlling for menopausal status.
DFS was defined as in the respective trial manuscripts as the length of
time from the date of randomization to any relapse including ipsilateral
breast recurrence or the appearance of a second primary malignancy
(including contralateral breast cancer), or death, whichever occurred first.
Hazard ratios (HRs), two-sided 95% confidence intervals (CIs) and
statistical tests were estimated from Cox proportional hazards models.
The nonparametric subpopulation treatment effect pattern plot (STEPP)
methodology [15] was used to investigate trends in treatment effect
differences across the continuum of p27 expression; a meaningful
STEPP analysis could not be undertaken for Skp2 because of the highly
skewed distribution. The analysis used SAS version 9.1 (SAS Institute
Inc., Cary, NC) and S-PLUS version 6.1 (Insightful Corp., Seattle, WA).
results
A total of 647 (61%) of 1063 premenopausal patients from
IBCSG trial VIII and 984 (59%) of 1669 postmenopausal
patients from IBCSG trial IX had tumor material available and
assessable for p27 and/or Skp2 immunoreactivity and were
included in the analysis. Median age at randomization was 45
years [interquartile range (IQR) 41–48 years] and 61 years (IQR
56–65 years) among premenopausal and postmenopausal
patients, respectively. In total, 705 (43%) patients had been
randomized to receive endocrine therapy alone (198 goserelin
and 507 tamoxifen) and 703 (43%) to chemo-endocrine
therapy (226 CMF~goserelin; 477 CMF~tamoxifen). Median
duration of follow-up was 10 years in the analysis cohort (9.4
and 10.3 years in the analysis cohorts from trials VIII and IX,
respectively). The analysis cohorts are representative of the
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overall trial cohorts (data not shown), with the exception of an
underrepresentation of patients with smaller and lower grade
tumors in the analysis cohort.
p27 and Skp2 immunoreactivity
The median level of tumor p27 expression was 44% (IQR 15%–
76%; range, 0%–98%) immunoreactive cells and 55% (875 of
1598) of patients’ tumors were classified as having low p27
expression (i.e. <50% immunoreactive cells). Among
premenopausal patients, the median p27 expression was 42%
(IQR 16%–74%) and among postmenopausal patients in trial
IX, the median expression was 46% (IQR 15%–77%). In total,
56% and 54% of pre- and postmenopausal patients’ tumors
were classified as having low p27 expression, respectively, and
thus low p27 expression was independent of menopausal status
(P = 0.28, Table 1).
Table 1. Patient menopausal status and tumor features according to tumor p27 and Skp2 expression status
p27 Skp2
Low (<50%) Normal (‡50%) P value Normal (<10%) High (‡10%) P value
Patients, n (%) 875 (55) 723 (45) 1274 (80) 315 (20)
Menopausal status 0.28 <0.001
Premenopausal 357 (56) 275 (44) 480 (75) 157 (25)
Postmenopausal 518 (54) 448 (46) 794 (83) 158 (17)
ER <0.001 <0.001
Absent (0%) 261 (83) 54 (17) 168 (53) 150 (47)
Present (‡1%) 603 (48) 664 (52) 1093 (87) 162 (13)
Median ER% (IQR) 71% (0–90) 90% (75–95) 90% (62–95) 2% (0–88)
PgR <0.001 <0.001
Absent (0%) 367 (74) 132 (26) 322 (64) 179 (36)
Present (‡1%) 498 (46) 587 (54) 941 (88) 134 (12)
Median PgR% (IQR) 10% (0–76) 60% (5–90) 45% (0–90) 0% (0–60)
ER/PgR status <0.001 <0.001
ER2/PgR2 251 (83) 51 (17) 161 (53) 144 (47)
ER2/PgR+ 10 (77) 3 (23) 7 (58) 5 (42)
ER+/PgR2 114 (58) 81 (42) 159 (82) 34 (18)
ER+/PgR+ 485 (46) 580 (54) 928 (88) 128 (12)
HER2 0.006 0.02
Overexpressed (3+) 157 (63) 93 (37) 186 (74) 64 (26)
Not (0, 1+, 2+) 713 (53) 625 (47) 1080 (81) 251 (19)
ER/PgR/HER2 status <0.001 <0.001
ER2/PgR2/HER22 178 (82) 39 (18) 108 (50) 110 (50)
Other 691 (50) 683 (50) 1160 (85) 204 (15)
Ki-67 LI <0.001 <0.001
Normal (<19%) 318 (47) 352 (53) 628 (94) 40 (6)
High (‡19%) 458 (58) 334 (42) 548 (69) 244 (31)
Median KI-67 LI% (IQR) 22% (13–39) 18% (11–28) 17% (11–27) 43% (26–66)
Tumor grade <0.001 <0.001
1 89 (37) 152 (63) 224 (95) 13 (5)
2 346 (50) 342 (50) 598 (88) 83 (12)
3 407 (66) 211 (34) 403 (65) 216 (35)
Tumor size (cm) 0.04 <0.001
£2 488 (53) 441 (47) 784 (85) 138 (15)
>2 368 (58) 267 (42) 455 (72) 177 (28)
Skp2 <0.001 –
Normal (<10%) 643 (52) 600 (48) – –
High (‡10%) 208 (66) 105 (34) – –
Unknown 24 18 – –
Median Skp2% (IQR) 0% (0–5) 0% (0–2) – –
p27 <0.001
Normal (‡50%) – – 600 (85) 105 (15)
Low (<50%) – – 643 (76) 208 (24)
Unknown – – 31 2
Median p27% (IQR) – – 47% (16–80) 36% (13–60)
Percentages sum across the rows; there are patients with unknown values of the different tumor features.
ER, estrogen receptor; IQR, interquartile range; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LI, labeling index.
original article Annals of Oncology
662 | Ravaioli et al. Volume 19 |No. 4 | April 2008
The median level of tumor Skp2 expression was 0% (IQR
0%–5%; range 0%–95%) immunoreactive cells, indeed only
43% (686 of 1589) showed any reactive cells, and 20% (315 of
1589) of patients’ tumors were classified as having high Skp2
expression (i.e. ‡10% immunoreactive cells). Among
premenopausal patients, the median level was 0.5% (IQR
0%–5%) and among postmenopausal patients was 0% (IQR
0%–3%). In total, 25% and 17% of pre- and postmenopausal
patients’ tumors were classified as having high Skp2 expression,
respectively, which was significantly different (P < 0.001).
There was an inverse relationship between p27 and Skp2
immunoreactivity; 66% of tumors expressing high Skp2 also
had low p27 immunoreactivity as compared with 52% of
tumors expressing normal Skp2 levels (P < 0.001). This
relationship was independent of menopausal status: among
premenopausal patients, 66% versus 53% of tumors
expressing high versus normal Skp2 also had low p27
immunoreactivity, and among postmenopausal patients 66%
versus 51% of tumors having high versus normal Skp2
expression also had low p27 immunoreactivity. Overall, 13%
(208/1556 with both p27 and Skp2 measured) of tumors
expressed high Skp2 and low p27.
In univariate analyses, low p27 immunoreactivity was
associated with higher tumor grade, larger tumor size, high
Ki-67 LI, ER-absent, PgR-absent and HER2 overexpressing
tumors (each P < 0.05, Table 1). In total, 82% of tumors
that did not express ER or PgR and did not overexpress HER2
also had low p27 immunoreactivity, thus it appears that low
p27 expression is commonly found in association with the
so-called triple-negative phenotype. In multivariable logistic
regression analyses controlling for menopausal status, the ER
and PgR status of the tumor and tumor grade remained
statistically significant in the final model (each P < 0.01).
Interactions between the variables were explored but none
were found to be statistically significant.
Similarly, in univariate analyses, high Skp2 immunoreactivity
was associated with higher tumor grade, larger tumor size,
high Ki-67 LI, ER-absent, PgR-absent and HER2
overexpressing tumors (each P < 0.05, Table 1). In
multivariable logistic regression analyses controlling for
menopausal status, the ER and Ki-67 LI status of the tumor
and the tumor grade and size remained statistically
significant in the final model (each P < 0.01). Interactions
between the variables were explored but none were found to
be statistically significant.
Finally, to the multivariable logistic regression model for
p27 expression status (which included menopausal status, ER,
PgR and grade), Skp2 expression status was added and
interactions of Skp2 with other variables were explored—in
particular with ER status and HER2 status. When Skp2
expression status was added to the model, it was not
associated with p27 immunoreactivity (P = 0.97). There was
a suggestion of an interaction of Skp2 with ER status
(P = 0.08), which would indicate that the association of Skp2
with p27 status differs depending on whether or not the tumor
expresses ER: among tumors with ER present, low p27
immunoreactivity was observed more often in high than in
normal Skp2-expressing tumors (54% versus 47% unadjusted),
whereas among tumors absent of ER, low p27 was observed
less often in high than in normal Skp2-expressing tumors
(80% versus 86% unadjusted) (Figure 1). When the interaction
with HER2 status was also considered, there was no
evidence that HER2 status influenced the association of p27
and Skp2 immunoreactivity.
patient outcome for endocrine-responsive tumors
Low p27 immunoreactivity was not associated with DFS
(HR = 1.15, 95% CI = 0.93–1.41, P = 0.21) nor was high Skp2
expression associated with DFS (HR = 1.30, 95% CI = 0.98–
1.74, P = 0.07) in univariate analyses among patients with ER-
expressing tumors (Figure 2). There was no evidence of
interaction of p27 and Skp2 statuswithDFS (P = 0.55) (Figure 2C).
Because of the associations of other tumor features with
p27 and Skp2 expression, we examined whether there was
heterogeneity in their relationship with DFS according to
subgroups defined by other tumor features (i.e. interactions).
There was no other tumor feature for which the association
of p27 status with DFS clearly varied in subgroups from the
overall effect (data not shown). There was also no evidence
of an interaction of p27 status with randomized treatment
regimen (P = 0.42), indicating that the treatment effect was
not different among patients with tumors expressing low p27
(HR = 0.99, 95% CI = 0.73–1.35 comparing chemo-endocrine
versus endocrine therapy alone) and those with normal p27
(HR = 0.84, 95% CI = 0.61–1.16). This is further illustrated
in the STEPP analysis of 10-year DFS according to
quantitative degree of p27 immunoreactivity of the tumor
(Figure 3). There is no clear pattern of benefit for one
treatment as compared with the other across p27 levels, nor
is there a clear pattern to indicate that endocrine therapy
alone might be less effective at lower levels of p27 expression
as the curve remains near 69% of 10-year DFS for all degrees
of p27 immunoreactivity.
Similarly for Skp2, there was no other tumor feature for
which the association of Skp2 status with DFS clearly varied
in subgroups from the overall association. There was no
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Figure 1. Frequency of low p27 immunoreactivity according to Skp2 and
estrogen receptor status of the tumor. Tumor p27 expression was
considered as low for <50% and as normal for ‡50% immunoreactive cells;
Skp2 expression was considered as high for ‡10% and as normal for <10%
immunoreactive cells.
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interaction with treatment regimen (P = 0.48), indicating
that the treatment effect was not different among patients
with tumors expressing high Skp2 (HR = 1.07, 95%
CI = 0.60–1.93) and those with normal Skp2 (HR = 0.88,
95% CI = 0.69–1.13) (Figure 4).
patient outcome for endocrine-nonresponsive
tumors
The univariate associations of menopausal status,
randomized treatment regimen and tumor factors with DFS
among the 324 patients with tumors absent of ER expression
were also studied. No variable, other than treatment regimen,
was statistically significantly associated with DFS, including
p27 status (P = 0.70) and Skp2 status (P = 0.30). A STEPP
analysis of 10-year DFS according to p27 expression of the
tumor shows consistent benefit of chemo-endocrine versus
endocrine therapy alone, regardless of p27 level (Figure 5).
There was a suggestion of a greater benefit of chemo-endocrine
therapy at the very lowest levels of p27 expression, both
because of a slightly better outcome on chemo-endocrine
therapy and because of slightly poorer outcome on endocrine
therapy alone, among the subpopulations of patients with
tumors having the lowest degree of p27 immunoreactivity.
Thus, if we consider quantitative degrees of p27 expression,
there is some evidence that among patients with tumors
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Figure 2. Disease-free survival among patients with estrogen receptor-
expressing tumors, by (A) tumor p27 status; (B) Skp2 status and (C) both
p27 and Skp2 status. Tumor p27 expression was considered as low for
<50% and as normal for ‡50% immunoreactive cells; Skp2 expression was
considered as high for ‡10% and as normal for <10% immunoreactive
cells.
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Figure 3. Subpopulation treatment effect pattern plot (STEPP) analysis of
disease-free survival (DFS) among patients with estrogen receptor-
expressing tumors, according to p27 immunoreactivity of the tumor. The
analysis uses a sliding-window approach to define several overlapping
subpopulations of patients on the basis of the level of p27
immunoreactivity. The x-axis indicates the median value of p27 for
patients and the y-axis indicates the 10-year DFS for patients in each
subpopulation. Each subpopulation contains 170 patients and slides by
30 patients.
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absent of ER expression, the benefit of chemo-endocrine
versus endocrine alone may be modified by p27 expression;
we did not see this in patients with ER-expressing tumors.
discussion
Many studies, mainly on tumor material obtained from
unselected populations of patients treated outside randomized
clinical trials or with limited clinical follow-up, have indicated
a prognostic or predictive value of low p27 expression, high
Skp2 expression or both in patients with early breast cancer [3,
16–19] and other tumor types [20–24]. Our group has
previously shown that low p27 expression was not associated
with prognosis in a cohort of node-positive and node-negative
early breast cancer patients treated with CMF-based
chemotherapy [5]; in addition, these data indicated an inverse
relationship between low p27 immunoreactivity and HER2
overexpression and a benefit of perioperative CMF
chemotherapy in patients with tumors showing low p27 levels.
The findings of the current study confirm in a larger
population that low p27 does not have an independent
prognostic role in early breast cancer patients with node-
negative disease, and show that high expression of Skp2 is also
not associated with prognosis. These results, however, shed
more light on the relationship between these two markers
involved in cell cycle regulation and their relationship to other
routinely used markers of treatment responsiveness, in
particular hormone receptor status and HER2 status.
In the evaluation of patients of IBCSG trials VIII and IX, an
inverse relationship between p27 and Skp2 was found: 66% of
tumors expressing high Skp2 also had also low p27. Overall,
13% of tumors expressed high Skp2 and low p27. We did not
observe relationships between antiestrogen actions and p27/
Skp2 values, meaning that the biological activation/inactivation
pathways are more complex.
A recent paper [3], analyzing 338 patients of which about
half had node-positive and half node-negative disease and 71%
had ER-positive tumors, found 34% of these patients with
tumors having both high Skp2 and low p27. The authors
observed that this group had a significantly worse DFS
including the subgroup with node-negative disease. On the
other hand, in the univariate analysis normal p27 was not
associated with worse DFS in this subgroup. It is, however,
important to highlight that this cohort of patients was not
analyzed within ER-positive and ER-negative cohorts and
included patients with node-negative and node-positive
disease treated heterogeneously. In our cohort of patients,
13% had low p27/high Skp2 and all had node-negative
disease, we observed no association between normal/low p27
and DFS or between high/normal Skp2 and DFS among
patients with endocrine-responsive tumors.
Several authors have indicated that p27 and/or Skp2 have
some value in predicting response to breast cancer treatments
[14, 15, 19, 25, 26]. In our study, considering patients with
endocrine-responsive and nonresponsive tumors separately,
relative effects of chemo-endocrine versus endocrine therapy
on DFS were similar regardless of p27 or Skp2 status. The
findings indicated a larger benefit for the subgroup of
patients with ER-absent tumors with particularly low levels
of p27 receiving CMF chemotherapy before endocrine
therapy as compared with endocrine therapy alone. These
results are consistent with our previous study [5]. However,
on the basis of the data presented in this report we cannot
recommend routine determination of p27 and Skp2 outside
clinical trials in any population of patients, particularly as
predictor of treatment responsiveness.
The molecular machinery regulating cell cycle and in
particular the entry into cell cycle and the transition from G0
to G1 is known to be complex and not restricted to the two
molecules studied here, despite their key role. The data of
Radke et al. [27] support a model where different pathways,
some Skp2 dependent and some Skp2 independent, may
converge and lead to p27 inactivation. Moreover, recent
research has shown an association of breast tumors with the
so-called triple-negative phenotype (ER/PgR/HER2-negative)
with unfavorable prognosis[28]. The common down-
regulation of p27 in these tumor types found in our study
indicates that strategies interfering with p27 inactivation could
be potentially useful in this particular tumor type, where
innovative treatments are needed. In addition, p27
inactivation during the development of resistance to anti-HER2
treatment (e.g. trastuzumab) should be studied in the future
context of this targeted therapy.
Our results confirm an inverse relationship between p27
and Skp2 expression which was independent of menopausal
status and the association of low p27 and high Skp2 with
other unfavorable prognostic features of the tumor. We
observed a possible interaction between Skp2 and ER status
in their relationship with p27 status, but this interaction was
not statistically significant. This relationship should be
further investigated, and emphasizes the need to carefully
consider ER status of the tumors when studying the
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Figure 5. Subpopulation treatment effect pattern plot (STEPP) analysis of
10-year disease-free survival (DFS) among patients with tumors absent of
estrogen receptors, according to p27 immunoreactivity of the tumor. The
analysis uses a sliding-window approach to define several overlapping
subpopulations of patients on the basis of the level of p27
immunoreactivity. The x-axis indicates the median value of p27 for
patients and the y-axis indicates the 10-year DFS for patients in each
subpopulation. Each subpopulation contains 110 patients and slides by
10 patients
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relationship of p27 and Skp2. We did not observe
a prognostic or predictive role of p27 or Skp2. DFS and the
relative effects of chemo-endocrine versus endocrine therapy
alone as used in these trials were not influenced by p27 and
Skp2 immunoreactivity.
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